SCHEMBL3003734

SCHEMBL3003734

COc1ccc(S(=O)(=O)C2CCN(c3nc(-c4cccc(C)c4)cs3)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.54
HSD17B10 Q99714 3/20 0.54
USP2 O75604 1/20 0.54
RECQL P46063 1/20 0.54
SMN1; SMN2 Q16637 7/20 0.52
RAB9A P51151 5/20 0.52
ALDH1A1 P00352 7/20 0.50
LMNA P02545 6/20 0.50
MAPK1 P28482 4/20 0.50
HTT P42858 3/20 0.50
TP53 P04637 2/20 0.50
TSHR P16473 1/20 0.50
GAA P10253 1/20 0.50
MMP1 P03956 1/20 0.49
MMP3 P08254 1/20 0.49
MMP7 P09237 1/20 0.49
MMP9 P14780 1/20 0.49
NPC1 O15118 4/20 0.48
HPGD P15428 1/20 0.47
KMT2A Q03164 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3010006 0.92 MAPT (0.64) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3011542 0.91 SMN1; SMN2 (0.54) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3010156 0.91 SMN1; SMN2 (0.52) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3006872 0.91 MAPT (0.61) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3017544 0.90 MAPT (0.54) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3013343 0.89 MAPT (0.66) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3020525 0.89 RAB9A (0.49) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3007857 0.89 SMN1; SMN2 (0.51) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3001245 0.89 SMN1; SMN2 (0.49) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3017062 0.89 MAPT (0.56) MAPTHSD17B10USP2RECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.